title: Buried dysplasia and early adenocarcinoma arising in barrett esophagus after porfimer-photodynamic therapy.
abstract: The restoration of squamous epithelium after photodynamic therapy (PDT) for Barrett esophagus (BE) and its related neoplasms has been noted. It may result in the development of buried neoplasms and/or BE underneath restored squamous epithelium which maintain their potential for malignant transformation. The purpose of this study was to evaluate the prevalence, endoscopic, and histologic characteristics and also response to further treatment of buried neoplastic epithelium developing after PDT. Fifty-two BE patients with high-grade dysplasia (n=19), intramucosal adenocarcinoma (n=28), and invasive adenocarcinoma (n=5) were treated with porfimer PDT. Buried neoplasms completely covered by squamous epithelium were seen in 1 patient before and in 13 patients after PDT. Their prevalence was 0.6% and 7.4% of pre and post-PDT biopsy levels positive for neoplasia (P=0.001). Buried neoplasms, representing the highest grade of residual neoplasm, were noted in a series of 11 post-PDT endoscopies (7.1% of 155 post-PDT endoscopies with neoplastic diagnoses) of 8 patients. Their occurrence after PDT was neither associated with the length of BE, the diffuseness of neoplasms nor the presence of buried lesions before treatment. There was no prevalent location for these lesions in relation to the original segment of BE, although the majority of both surface and buried neoplasms were found in the prior neoplastic sites. Patients with buried neoplasms responded to further treatment similarly to those with only surface neoplasms (8 of 13 vs. 17 of 24) (P=0.33). In conclusion, buried neoplasms are not uncommon after PDT. Thorough endoscopic surveillance with extensive biopsies, especially of the sites previously positive for neoplasia is important to avoid overlooking buried neoplasms that may progress.
authors.affiliation: Department of Pathology, Gastrointestinal Pathology Service, Massachusetts General Hospital, Boston, MA 02114-2696, USA.
authors.forename: Mari
authors.initials: M
authors.lastname: Mino-Kenudson
authors.forename: Shinichi
authors.initials: S
authors.lastname: Ban
authors.forename: Masaya
authors.initials: M
authors.lastname: Ohana
authors.forename: William
authors.initials: W
authors.lastname: Puricelli
authors.forename: Vikram
authors.initials: V
authors.lastname: Deshpande
authors.forename: Michio
authors.initials: M
authors.lastname: Shimizu
authors.forename: Norman S
authors.initials: NS
authors.lastname: Nishioka
authors.forename: Gregory Y
authors.initials: GY
authors.lastname: Lauwers
mesh_terms: D000230:Adenocarcinoma / Q000188:drug therapy / Q000209:etiology / Q000473:pathology*; D000368:Aged; D000369:Aged, 80 and over; D001471:Barrett Esophagus / Q000150:complications / Q000188:drug therapy / Q000473:pathology; D017323:Dihematoporphyrin Ether / Q000627:therapeutic use*; D004938:Esophageal Neoplasms / Q000188:drug therapy / Q000209:etiology / Q000473:pathology*; D004945:Esophagoscopy; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local; D010778:Photochemotherapy; D017319:Photosensitizing Agents / Q000627:therapeutic use*; D011230:Precancerous Conditions / Q000188:drug therapy / Q000209:etiology / Q000473:pathology*
chemical_list: D017319:Photosensitizing Agents; D017323:Dihematoporphyrin Ether